The U.S. Food and Drug Administration has approved GlaxoSmithKline’s Incruse Ellipta (umeclidinium) as a treatment for patients with chronic obsessive pulmonary disease, according to a Medscape report ...
The FINANCIAL — GlaxoSmithKline plc on October 20 announced positive results from two head-to-head studies directly comparing the efficacy and safety of Incruse Ellipta (umeclidinium) to two available ...
The FDA’s acceptance for filing of our ANDA for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy® Ellipta®, is another major milestone in advancing our ...
Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for ...
In a 12-week late stage trial, Glaxo's (GSK-1%) Incruse Ellipta (umeclidinium) achieved its primary endpoint of a statistically significant improvement in lung function when compared to placebo as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results